Cargando…

Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick

BACKGROUND: Although legislation permits New Brunswick pharmacy professionals to administer a wide range of immunizations, public funding for these services is currently limited to immunizations against influenza and COVID-19 and was recently extended to include pneumococcal immunization (Pneu23) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Folkins, Chris, Gorman-Asal, Madeleine, Brewster, Clark, Foster, Rebecca, Gulliver, Adrienne, Thomson, Emily, Singh, Paramdeep, Miah, Pablo, Magalhaes, Sandra, McDonald, J. Ted
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331360/
https://www.ncbi.nlm.nih.gov/pubmed/37435502
http://dx.doi.org/10.1177/17151635231176498
_version_ 1785070240972931072
author Folkins, Chris
Gorman-Asal, Madeleine
Brewster, Clark
Foster, Rebecca
Gulliver, Adrienne
Thomson, Emily
Singh, Paramdeep
Miah, Pablo
Magalhaes, Sandra
McDonald, J. Ted
author_facet Folkins, Chris
Gorman-Asal, Madeleine
Brewster, Clark
Foster, Rebecca
Gulliver, Adrienne
Thomson, Emily
Singh, Paramdeep
Miah, Pablo
Magalhaes, Sandra
McDonald, J. Ted
author_sort Folkins, Chris
collection PubMed
description BACKGROUND: Although legislation permits New Brunswick pharmacy professionals to administer a wide range of immunizations, public funding for these services is currently limited to immunizations against influenza and COVID-19 and was recently extended to include pneumococcal immunization (Pneu23) in individuals aged 65 years or older. We used administrative data to project health and economic outcomes associated with the current Pneu23 program and with extension of public funding to include: 1) younger adults aged 19 years or older in the Pneu23 program, and 2) tetanus boosters (Td/Tdap). METHODS: Two model scenarios were compared: a Physician-Only model in which physicians remain the only practitioners to administer publicly funded Pneu23 and Td/Tdap, and a Blended model in which this service is also provided by pharmacy professionals. Immunization rates by practitioner type were projected based on physician billing data accessed via the New Brunswick Institute for Research, Data and Training in conjunction with trends observed with influenza immunization by pharmacists. These projections were used along with published data to estimate health and economic outcomes under each model. RESULTS: Public funding of Pneu23 (65+), Pneu23 (19+) and Td/Tdap (19+) administration by pharmacy professionals is projected to yield increased immunization rates and physician time savings compared with the Physician-Only model. Public funding of Pneu23 and Td/Tdap administration by pharmacy professionals in those aged ≥19 years would result in cost savings, owing primarily to productivity losses avoided in the working age population. DISCUSSION: Increased immunization rates, physician time savings and cost savings may be realized if public funding were extended to include administration of Pneu23 in younger adults and Td/Tdap, by pharmacy practitioners.
format Online
Article
Text
id pubmed-10331360
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-103313602023-07-11 Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick Folkins, Chris Gorman-Asal, Madeleine Brewster, Clark Foster, Rebecca Gulliver, Adrienne Thomson, Emily Singh, Paramdeep Miah, Pablo Magalhaes, Sandra McDonald, J. Ted Can Pharm J (Ott) Research and Clinical BACKGROUND: Although legislation permits New Brunswick pharmacy professionals to administer a wide range of immunizations, public funding for these services is currently limited to immunizations against influenza and COVID-19 and was recently extended to include pneumococcal immunization (Pneu23) in individuals aged 65 years or older. We used administrative data to project health and economic outcomes associated with the current Pneu23 program and with extension of public funding to include: 1) younger adults aged 19 years or older in the Pneu23 program, and 2) tetanus boosters (Td/Tdap). METHODS: Two model scenarios were compared: a Physician-Only model in which physicians remain the only practitioners to administer publicly funded Pneu23 and Td/Tdap, and a Blended model in which this service is also provided by pharmacy professionals. Immunization rates by practitioner type were projected based on physician billing data accessed via the New Brunswick Institute for Research, Data and Training in conjunction with trends observed with influenza immunization by pharmacists. These projections were used along with published data to estimate health and economic outcomes under each model. RESULTS: Public funding of Pneu23 (65+), Pneu23 (19+) and Td/Tdap (19+) administration by pharmacy professionals is projected to yield increased immunization rates and physician time savings compared with the Physician-Only model. Public funding of Pneu23 and Td/Tdap administration by pharmacy professionals in those aged ≥19 years would result in cost savings, owing primarily to productivity losses avoided in the working age population. DISCUSSION: Increased immunization rates, physician time savings and cost savings may be realized if public funding were extended to include administration of Pneu23 in younger adults and Td/Tdap, by pharmacy practitioners. SAGE Publications 2023-07-07 /pmc/articles/PMC10331360/ /pubmed/37435502 http://dx.doi.org/10.1177/17151635231176498 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research and Clinical
Folkins, Chris
Gorman-Asal, Madeleine
Brewster, Clark
Foster, Rebecca
Gulliver, Adrienne
Thomson, Emily
Singh, Paramdeep
Miah, Pablo
Magalhaes, Sandra
McDonald, J. Ted
Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick
title Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick
title_full Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick
title_fullStr Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick
title_full_unstemmed Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick
title_short Projected health and economic outcomes of extending public funding of pharmacy services to include administration of Pneu23 and Td/Tdap immunizations by pharmacy practitioners in New Brunswick
title_sort projected health and economic outcomes of extending public funding of pharmacy services to include administration of pneu23 and td/tdap immunizations by pharmacy practitioners in new brunswick
topic Research and Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331360/
https://www.ncbi.nlm.nih.gov/pubmed/37435502
http://dx.doi.org/10.1177/17151635231176498
work_keys_str_mv AT folkinschris projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT gormanasalmadeleine projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT brewsterclark projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT fosterrebecca projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT gulliveradrienne projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT thomsonemily projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT singhparamdeep projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT miahpablo projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT magalhaessandra projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick
AT mcdonaldjted projectedhealthandeconomicoutcomesofextendingpublicfundingofpharmacyservicestoincludeadministrationofpneu23andtdtdapimmunizationsbypharmacypractitionersinnewbrunswick